Skip to content
← Full study record

NCT02254551 · MORE INFO

Limitations, agreements, and source contact

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma · Source last updated 2017-02-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
Early termination of study during dose-escalation did not support continuation of study.
point Of Contact
email
charles.davis2@scri-innovations.com
organization
Sarah Cannon Development Innovations
phone
615-524-4341
title
Charles Davis, Sr Mgr Regulatory Strategy & Operations
Complete source fields
certain Agreement
other Details
The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
Early termination of study during dose-escalation did not support continuation of study.
point Of Contact
email
charles.davis2@scri-innovations.com
organization
Sarah Cannon Development Innovations
phone
615-524-4341
title
Charles Davis, Sr Mgr Regulatory Strategy & Operations

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice